You are on page 1of 8

Ask the Expert

Events
Presentations
Videos
Products & Services
Cool Tools
DON'T MISS
The Dishs Weekly Biotechnology News Wrap Up October 6, 2017Posted 1 week ago
Cool Tool Efficient single cell isolation and proof of clonality in one stepPosted 1 week ago
Ask the Expert Everything you ever wanted to ask about Corning Matrigel MatrixPosted 2 weeks ago
The Dishs Weekly Biotechnology News Wrap Up September 29, 2017Posted 2 weeks ago
BPI East is next week! Hope to see you there dont miss these great talks and activities!Posted 3 weeks ago
The Dishs Weekly Biotechnology News Wrap Up September 22, 2017Posted 3 weeks ago
The Dishs Weekly Biotechnology News Wrap Up September 15, 2017Posted 4 weeks ago
The Dishs Weekly Biotechnology News Wrap Up October 13, 2017Posted 3 hours ago
A Novel 3D Immune Oncology Model for High Throughput Testing of Tumoricidal CapabilityPosted 21 hours ago
Single-use bioreactors for fermentation Its now a reality that deserves considerationPosted 2 days ago

Home > Upstream Bioprocessing > Cell Lines > Perfusion Bioreactors -With so much to offer they deserve a closer
look

Perfusion Bioreactors -With so much to


offer they deserve a closer look
By bsargent on June 12, 2013

inShar e61

Introduction to Biopharmaceutical
Manufacturing
In the biopharmaceutical industry there is an ever-present drive to increase product yield and reduce
cost. The industry is driven in this direction, not only by the drive to improve manufacturing
techniques, but also by pressure from the government, physicians, and patients to reduce the overall
cost of medications. However these cost savings must be achieved without compromising high
safety standards.

Since the inception of biopharmaceutical manufacturing in the 1980s there have been continual
improvements to the process. These improvements have culminated in the most common approach
to biopharmaceutical manufacturing, fed batch suspension culture, most commonly expressed in
CHO cells. While improvements have continued in areas including advancements in cloning, media
formulation, removal of animal components, and downstream purification resins and columns, there
has been little change to the actual fed batch paradigm. One technology that could perhaps make a
big change in how biopharmaceuticals are manufactured is the use of perfusion bioreactors.
Perfusion technology has improved extensively since its creation and its application to large-scale
manufacturing and other applications in the production of biologics deserves a second, closer look.

How Perfusion Bioreactors Work


Traditional fed-batch bioreactor systems consist of tanks that are usually between 10,000-25,000
liters. Cells are cultured in batches that typically run between 7-21 days by which time media
nutrients have been consumed and toxic waste has begun to accumulate. During the run, cells
secrete the protein of interest into the media and at the end of the run the protein is separated from
cell mass as a batch. Typical product yields are in the range of 1 to 4 grams per liter depending on
the clone and antibody. While regular improvements have moved product yield from under 1 gram
per liter to where they are now, it has not improved other issues in fed batch manufacturing including
large manufacturing footprints and challenges with scalability.

In contrast, perfusion bioreactors culture cells over much longer periods, even months, by
continuously feeding the cells with fresh media and removing spent media while keeping cells in
culture. In perfusion there are different ways to keep the cells in culture while removing spent media.
One way is to keep the cells in the bioreactor by using capillary fibers or membranes, which the cells
bind to. Another does not bind the cells, but rather relies on filtration systems that keep the cells in
the bioreactor while allowing the media to be removed. Another method is the use of a centrifuge to
separate cells and return them to the bioreactor.

Examples of cell separation methods:


GE Healthcares Hollow Fiber Microfiltration Cartridges In this system, the retentate
consists of the cells, which flow past the membrane and are sent back to the bioreactor. The
spent medium is the permeate that passes through the membrane.
ATMIs iCELLis Single Use Fixed Bed In this system, cells are bound to custom
microcarriers, which allows cells to stay in place while media flows around them.
Centrifuge method In this system, a centrifuge is used to separate cells from culture media
and then cells are returned to the bioreactor.

Advantages of Perfusion
Product Quality and Stability
By continuously removing spent media and replacing it with new media, nutrient levels are
maintained for optimal growing conditions and cell waste product is removed to avoid toxicity. In
addition, the product is regularly removed before being exposed to excessive waste that causes
protein degradation. Product is also harvested and purified much more quickly, which is particularly
helpful when producing a product that is unstable.

Scalability
With fed batch culture, demand quickly outpaces pilot scale facilities and more bioreactors need to
be added to increase production. With the addition of additional bioreactors comes a decision, either
to outsource to a contract manufacturer or build out a larger dedicated manufacturing space. Once
the facility is built, scale flexibility is difficult. It takes money to operate the facility even if no drugs
are being manufactured there. If for some reason demand goes down, companies can find
themselves with a lot of costly extra capacity.

Perfusion bioreactors offer several advantages over traditional fed-batch bioreactors when
addressing problems of scalability and increasing demand. Maybe the most critical advantage is that
perfusion bioreactors are smaller in size and can produce the same product yield in less space.
Typically perfusion bioreactors operate at 10-30x concentrations compared to fed-batch bioreactors.
For example, it has been shown that a 50-liter perfusion bioreactor can produce the same yield as a
1,000-liter fed-batch bioreactor. Therefore, the use of perfusion should enable the replacement of
typical 10,000 L bioreactors with 1,000L bioreactors without negatively impacting the yearly yield of
manufactured product.

This size advantage is important because it means that facilities dont need a significant increase in
space to increase production. Similarly, perfusion bioreactors require less on utilities cost and they
are less labor intensive to operate. Thus requiring significantly less capital investment on the front
end and less on operating costs to manufacture the same yield as fed-batch bioreactors.

Cost Savings
Some proponents have argued that considerable cost savings is a further benefit of perfusion
bioreactor manufacturing and this topic was covered in a previous blog titled Are Perfusion Cell
Culture Systems the Future for Cell Culture Based Biomanufacturing. The blog summarizes a talk
given by John Bonham-Carter on the cost savings found in the use of Refine Technologys ATF
System.

Large Scale Perfusion Bioreactors


Many mistakenly think that perfusion is only possible at small scale and in small bioreactors or that it
is too complex to be scalable to manufacturing. However, this is not the case and there have been
several success stories of the use of perfusion culture in large-scale manufacturing. For instance,
Remicade, one of the best selling biologics in the world, employs perfusion culture in manufacturing,
as does Bayer in their manufacture of Factor VIII.

To demonstrate how large scale perfusion manufacturing can be achieved with similar results to
smaller scale perfusion use, Xcellerex conducted a case study comparing 10 liter, 200 liter and
1,000 liter perfusion bioreactor culture. In the case study, Xcellerexs XDR 1,000 liter perfusion
disposable stirred tank bioreactor was used with a disposable mixing system and a disposable
centrifuge by Centritech. The use of disposables further simplified implementation of perfusion
culture and eliminated the time consuming cleaning and sterilization steps.
The 1,000 liter process was successfully operated for one month with 12 harvests over a 19 day
period. Supernatant was removed at a fixed rate, and sent to the centrifuge where cells were then
returned directly to bioreactor. New media was added regularly to maintain constant culture volume
in the bioreactor. Final results demonstrated that cell density, cell viability, protein production/yield
results were all comparable across 10 liter, 200 liter, and 1,000 liter perfusion bioreactor systems.

Beyond CHO based Biopharmaceutical


Manufacturing
Perfusion bioreactors are a key to the future of not just CHO-based biopharmaceutical
manufacturing, but also several other key manufacturing strategies, including cell based therapy
manufacturing, research and development, process development and vaccine manufacturing. In
fact, a real strength of perfusion bioreactors is their flexibility and adaptability to various cell lines and
applications. One example is the use of perfusion bioreactors in stem cell manufacturing; to learn
more, please see our previous blog titled, Identifying Options for Stem Cell Based Therapy Scale-
Up. Below I have included some additional examples of areas where perfusion bioreactors are
making a big impact.

Perfusion-based High Density Cell Banking


In the study, Development and Implementation of a Perfusion-based High Cell Density Banking
Process, published in Biotechnology
Progress, the Cell Culture Development group at Biogen Idec shared their expertise in using GE
Healthcares WAVE Bioreactor to create a perfusion-based

GE Healthcares WAVE Bioreactor 2050, courtesy of GE Healthcare.

high cell density cell banking process.

The current process for preparing cells for transfer into large-scale biopharmaceutical manufacturing
bioreactors is to expand the cells using seed train culture. This involves many time consuming steps
beginning with a small sample of cells taken from the working cell bank. Cells then undergo multiple
expansion steps until there is enough cells and culture volume for transfer to a large-scale
bioreactor. The novel process that Biogen Idec describes in the study simplifies this process and
reduces process time considerably.

In the study, the team describes their process of using perfusion culture to create a high-density cell
banking system that increased the number of viable cells and volume in each banked vial. The
perfusion bioreactor they selected for the task was the WAVE Bioreactor system with disposable 20-
liter Cellbags fit with an internal floating filter. The internal floating filter retains the cells in the
bioreactor and filters only the media thus eliminating the need for an external cell separator and flow
loop. This configuration was selected because it simplified the use of perfusion culture in the cell-
banking lab. Perfusion conditions were then optimized for high cell density culture, including
perfusion rate, rocking speed and aeration. Results demonstrated peak cell densities of greater than
20 x 106 cells/ml and maintenance of cell densities greater than or equal to 90%.
Creation of the high-density cell bank enabled direct inoculation of the high-density cell bank vials
into the WAVE Bioreactor, which eliminated the need for shake flask expansion. The paper states
Elimination of multiple culture expansion steps in the upstream seed train resulted in reduction of 9
days of manufacturing plant time, and also improved operational success in seed expansion steps.
Biogen Idec was then able to repeat their success in seven independent cell lines all producing
recombinant therapeutics and results have been verified in GMP clinical manufacturing campaigns.

Other research groups have successfully used the same floating filter perfusion technology in
cultures reaching 100 x 106 cells/ml or greater (Wang, et al., 20121).
For another application, please see our previous blog on the use of the WAVE Bioreactor for T-cell
expansion at T-cell Expansion Using Perfusion in Closed System Bioreactors.

Perfusion for Virus Production


Perfusion can also be very useful in the production of viruses for vaccine manufacturing. As demand
for vaccines grow, there is a challenge in how to scale up efficiently and increase virus production.
Current virus manufacturing systems include multi-tray

ATMIs iCELLis System

systems, roller bottles and for scale up, frequently bioreactors with microbeads are used.

While moving to a bioreactor with microbeads is a viable option, it does require a good deal of
process development and standard bioreactor mixing can inflict a good deal of shear stress on cells.
In addition, scaling up to bioreactor manufacturing often requires more space, which means capital
investment and an expansion of the current manufacturing footprint.
Another solution for increasing virus production is to employ the use of perfusion. One example
is ATMI LifeSciences Integrity iCELLis system. The iCELLis is a disposable, high-cell density
bioreactor that provides a very high ratio of surface area to volume. In 25 liters of volume, the
manufacturing scale iCELLis bioreactor provides 500 square meters of growing area, which is
equivalent to the surface of 3,000 roller bottles. This ratio allows for manufacturing expansion
without the need to increase the existing manufacturing footprint or incur capital expenditures.
It also enables a simplified seed train. With the iCELLis system, inoculation requirements are low
where the equivalent of 20 roller bottles can be sufficient to inoculate the entire growing area. By
using perfusion and circulating media using a magnetic drive impeller low shear stress and high cell
viability is maintained.

For more information on the use of the iCELLis system, please see the poster Linear Scalability
Virus Production Integrity iCELLis Single-Use Fixed-Bed Bioreactors, From Bench Scale to Industrial
Scale.

Perfusion-based Hollow Fiber Bioreactor Enables In


Vitro Bone Marrow Model
In the study, Co-culture of Stromal & Erytholeukemia Cells in a Perfused Hollow Fiber Bioreactor
System as an In Vitro Bone Marrow Model for Myeloid Leukemia, published in Biotechnology and
Bioengineering, the study authors described how they developed a hematopoietic co-culture system
using Fibercell Systems Hollow Fiber Bioreactor.
By using the hollow fiber bioreactor, study authors were able to create a culture environment that
more closely represented human bone marrow. The ability to achieve this superior model was due
largely to the capability of the hollow fiber bioreactor to support high cell densities and 3D cell
culture, thus allowing cells to behave in a way that was more similar to natural cell interactions. In
addition the use of the hollow fiber bioreactor with perfusion permitted culture to continue for two
weeks as compared with only one week using standard tissue culture techniques. Authors state,
With the advantage of achieving high cell densities and 3D cellular contact, the HFBR (hollow fiber
bioreactor) system recreates a closer mimicry of the cell-stroma microenvironment which can
provide significant improvements to in vitro studies of stroma-dependent leukemic and hematopoietic
cell functions. The creation of this model enables a superior method for studying leukemia and
supports exploration of the use of hollow fiber bioreactors as a way to create in vitro models for
studying disease.

In Conclusion
Despite stated advantages, the vast majority of biotherapeutics today are manufactured using
suspension CHO cells grown in fed-batch culture. However, this long held standard of fed-batch
suspension culture may be changing. Companies are beginning to explore the idea of continuous
processing and use of perfusion bioreactors are a key component of this strategy. Please see
Continuous Procesing: From Cookie Preparation to Cell-based Production, for more information on
continuous processing. In addition perfusion bioreactors are being used more commonly in
biopharmaceutical manufacturing including the manufacturing of Remicade, from Centocor and
Genzyme (Sanofi) and Centocor (J&J/Janssen ) have long employed perfusion culture in upstream
processes of some approved biopharmaceutical manufacturing.
So are perfusion bioreactors, the future of biopharmaceutical manufacturing? Please provide your
comments below.

References

1. Wang, L., Hu, H., Yang, J., Wang, F., Kaisermayer, C., & Zhou, P. (2012). High yield of human monoclonal
antibody produced by stably transfected Drosophila Schneider 2 cells in perfusion culture using wave
bioreactor. Molecular biotechnology, 52(2), 170-179.